Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.

Delavirdine mesylate (DLV) is a potent nonnucleoside reverse transcriptase inhibitor with activity specific for human immunodeficiency virus type 1. In the present phase I/II study we evaluated the safety, toxicity, pharmacokinetics, and antiretroviral activities of two-drug and three-drug combinati...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Davey, R T, Chaitt, D G, Reed, G F, Freimuth, W W, Herpin, B R, Metcalf, J A, Eastman, P S, Falloon, J, Kovacs, J A, Polis, M A, Walker, R E, Masur, H, Boyle, J, Coleman, S, Cox, S R, Wathen, L, Daenzer, C L, Lane, H C
Format: Artigo
Langue:Inglês
Publié: 1996
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC163391/
https://ncbi.nlm.nih.gov/pubmed/8807058
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires